Holen Sie sich die Stockscreener-App
4.975
0.30%
-0.015
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.99
Offen:
$5.04
24-Stunden-Volumen:
530.47K
Relative Volume:
0.32
Marktkapitalisierung:
$1.86B
Einnahmen:
$10.53B
Nettoeinkommen (Verlust:
$-1.23B
KGV:
-1.5327
EPS:
-3.246
Netto-Cashflow:
$949.99M
1W Leistung:
-3.77%
1M Leistung:
-8.21%
6M Leistung:
-28.21%
1J Leistung:
-15.82%
1-Tages-Spanne:
$4.935
$5.05
1-Wochen-Bereich:
$4.935
$5.325
52-Wochen-Spanne:
$4.93
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.975 | 1.86B | 10.53B | -1.23B | 949.99M | -3.246 |
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.015 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.23 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.65 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.64 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Actinic Keratosis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Almirall, Biofrontera Pharma, Vidac Pharma, Rubedo Life Sciences, Bausch Health, Sandoz Pharma - Barchart.com
TSX Healthcare Stocks: Which Names Are Drawing Market Attention? - Kalkine Media
BHC Q1 2026 Earnings: EPS Surges 12.33% Above Estimates, Shares Edge HigherEarnings Surprise Score - newsline.com
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia - Cantech Letter
Why Bausch Health Companies Inc stock is sliding today - Wealth Awesome
Barclays Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Is Bausch Health Finally Finding Its Comeback Moment? - Kalkine Media
Bausch Health: Invest In The Short-Term Bonds, Not The Stock (NYSE:BHC) - Seeking Alpha
Valeant Investors Should Get Cert. In PwC Fight, Report Says - Law360
Bausch Health Companies stock (CA0717341071): Canadian pharma name in focus after fresh institutiona - AD HOC NEWS
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Only 217 brands in China hold this mark. Thermage just earned it - Stock Titan
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China - PR Newswire
TSX Pharma Companies Building Regional Healthcare Reach - Kalkine Media
Bausch Health (BHC) director Amy Wechsler granted $250,000 in RSUs - Stock Titan
Bausch Health (NYSE: BHC) grants $250,000 RSU award to director Eiry Roberts - Stock Titan
Bausch Health (NYSE: BHC) director receives $250,000 RSU equity grant - Stock Titan
John Paulson (BHC) receives $250K RSU award and reports large fund holdings - Stock Titan
Bausch Health (BHC) director awarded $250K in RSUs - Stock Titan
Bausch Health (BHC) director awarded $250K in restricted share units - Stock Titan
Bausch Health (BHC) director Sarah Kavanagh receives $250,000 RSU grant - Stock Titan
Bausch Health (NYSE: BHC) director awarded 45,871 RSUs valued at $250,000 - Stock Titan
Director Garcia (BHC) receives $250,000 restricted share grant in Form 4 - Stock Titan
BHC Q1 2026 Earnings: EPS Surprises to the Upside Amidst Operational ExecutionGuidance Downgrade Alert - newsline.com
Bausch Health Cos (BHC) Stock Price, News & Analysis $BHC - MarketBeat
Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading PlayersDompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals - Yahoo Finance
Bausch Health (NYSE: BHC) director sells 24,456 shares under plan - Stock Titan
New Bausch Health (BHC) director Eiry Roberts added as insider on Form 3 - Stock Titan
BHC: Sustained growth, China expansion, and BLCO monetization drive strategic priorities - TradingView
Bausch Health shareholders elect board members and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Bausch Health shareholders elect board members and approve auditor at annual meeting - Investing.com
Shareholders of Bausch Health (NYSE: BHC) approve directors, pay and PwC - Stock Titan
Eiry Roberts to chair Bausch Health science and technology committee - Stock Titan
[144] Bausch Health Companies Inc. SEC Filing - Stock Titan
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. - Investing.com UK
Cannabis Pharmaceuticals Business Research Report 2026: An - GlobeNewswire
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth - Yahoo Finance
Bausch Health rises on Q1 double beat, 2026 guidance - MSN
Bausch Health Companies (BHC) price target decreased by 10.52% to 6.72 - MSN
Dry Eye Products Market Will Generate Booming Growth - openPR.com
BHC Stock Price, Quote & Chart | BAUSCH HEALTH COS INC (NYSE:BHC) - ChartMill
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference - The Globe and Mail
Hear Bausch Health chiefs in live RBC healthcare chat May 20 - Stock Titan
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference - 富途牛牛
Why BauschHealth (BHC) might be the steady performer you need (Technical Weakness) 2026-05-11IV Crush Alert - newsline.com
Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says - Moomoo
Bausch Health Cos (BHC) Earnings Date and Reports 2026 $BHC - MarketBeat
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe – Company Announcement - Financial Times
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging - Seeking Alpha
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.96%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):